CD274 and small cell lung carcinoma: The U.S. Food and Drug Administration (FDA) has approved the antiprogrammed cell death‐ligand 1 (PD‐L1) antibody atezolizumab in combination with carboplatin and etoposide as the first‐line treatment for adult patients with ES‐SCLC.3